Zegerid OTC, Private Label Omeprazole Add Drug Interaction Warnings
This article was originally published in The Tan Sheet
Executive Summary
CDER approves sNDAs from Bayer for Zegerid OTC powder and private label manufacturer Dexcel Pharma for omeprazole delayed release tablets to add label warnings on drug-drug interactions for methotrexate and mycophenolate mofetil.
You may also be interested in...
Private Label Competition For Zegerid OTC Sets Sail With Perrigo Launch
Perrigo's omeprazole and sodium bicarbonate capsules indicated for the treatment of frequent heartburn will bear labeling that has been through several updates since the first PPI became available OTC in 2004.
Private Label Competition For Zegerid OTC Sets Sail With Perrigo Launch
Perrigo's omeprazole and sodium bicarbonate capsules indicated for the treatment of frequent heartburn will bear labeling that has been through several updates since the first PPI became available OTC in 2004.
Infirst Extends Mylanta Brand With Nighttime Product, Chewable Tablets
Infirst changes the Mylanta Maximum Strength lemon-mint liquid with a "smoother, creamier formulation" and adds a vanilla caramel-flavored version and another liquid product, Mylanta Tonight, featuring a honey chamomile flavor. Also new are Mylanta Gas Minis chewable anti-gas tablets.